Document is current
Any future updates will be listed below
-
Authors
Kubota, Masahito
Bun, Shogyoku
Takahata, Keisuke
Kurose, Shin
Momota, Yuki
Iwabuchi, Yu
Tezuka, Toshiki
Tabuchi, Hajime
Seki, Morinobu
Yamamoto, Yasuharu
Shikimoto, Ryo
Mimura, Yu
Hoshino, Takayuki
Shimohama, Sho
Suzuki, Natsumi
Morimoto, Ayaka
Oosumi, Azusa
Hoshino, Yuka
Tai, Kenji
Aoyagi, Hirofumi
Sato, Yoshiaki
Kuromitsu, Junro
Nakahara, Jin
Mimura, Masaru
Ito, Daisuke
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006, JP17pc0101006)
- License Information
-
More Information
Article History
Received: 16 March 2025
Accepted: 2 June 2025
First Online: 7 June 2025
Declarations
:
: The Certified Review Board of Keio University (#N20170237) approved the study design and protocol. The study was conducted in accordance with the Declaration of Helsinki. All participants (plus their proxies as needed) provided written informed consent for participation in the study. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; , ID# UMIN000032027) and Japan Registry of Clinical Trials (jRCT; , ID# jRCTs031180225).
: Not applicable.
: DI has received honorariums from Daiichi Sankyo, Nihon Medi-Physics, Kowa, PDRadiopharma, Otsuka Pharmaceutical, Lilly and Eisai and has a joint research agreement with Sysmex. There are no other relationships or activities that could appear to have influenced the submitted work.
